Strona glówna
•
FAQ
•
Szukaj
•
Użytkownicy
•
Grupy
•
Galerie
•
Rejestracja
•
Profil
•
Zaloguj się, by sprawdzić wiadomości
•
Zaloguj
Forum Forum MESA !! Strona Główna
->
Terminarz
Napisz odpowiedź
Użytkownik
Temat
Treść wiadomości
Emotikony
Więcej Ikon
Kolor:
Domyślny
Ciemnoczerwony
Czerwony
Pomarańćzowy
Brązowy
Żółty
Zielony
Oliwkowy
Błękitny
Niebieski
Ciemnoniebieski
Purpurowy
Fioletowy
Biały
Czarny
Rozmiar:
Minimalny
Mały
Normalny
Duży
Ogromny
Zamknij Tagi
Opcje
HTML:
TAK
BBCode
:
TAK
Uśmieszki:
TAK
Wyłącz HTML w tym poście
Wyłącz BBCode w tym poście
Wyłącz Uśmieszki w tym poście
Kod potwierdzający: *
Wszystkie czasy w strefie EET (Europa)
Skocz do:
Wybierz forum
Nabór do ZESPÓŁ Forum MESA
----------------
Nabór
MESA - DRUŻYNY
----------------
GKS Bełchatów
Cracovia Kraków
Dyskobolia Grodzisk Wielkopolski
Górnik Zabrze
Jagiellonia Białystok
Korona Kielce
Lech Poznań
Legia Warszawa
ŁKS Łódź
Odra Wodzisław Śląski
Polonia Bytom
Ruch Chorzów
Wisła Kraków
Zagłębie Lubin
Zagłębie Sosnowiec
MESA - OGÓLNIE
----------------
Regulamin
Terminarz
Sędziowie
Wyniki
DLA KIBICA
----------------
Typer
Rozrywka
Sonda
INNE
----------------
Hydepark
Reklama
PARTNERZY
----------------
Parnerzy w reklamie i realizacji projektu !!
Przegląd tematu
Autor
Wiadomość
ncycgdxhl
Wysłany: Śro 8:30, 30 Mar 2011
Temat postu: TORCH study brings the treatment of chronic obstru
_772,
belstaff outlet
TORCH study brings the treatment of chronic obstructive pulmonary disease What is Enlightenment?
Medical information. However, TORCH study did not show consistent results with the SMART study. In the TORCH study, there are 1521 cases of patients receiving treatment for 3 years LABA alone, its all-cause mortality was only 13.5%, even lower than the placebo group, 15.2%. Although no significant difference between two groups of mortality, but the results can explain at least 3 years alone LABA treatment of COPD does not increase the risk of death. By LaVecchia and other _3j view, LABA and even protection. Some of the results of TORCH that salmeterol is a winner, and fluticasone losers l5j. Although some of the evaluation is simple, but raises a serious question whether we need to re-evaluate the treatment of ICS in COPD status? The main reason for using the ICS evidence based medicine ICS can reduce the rate of acute exacerbation of COPD, improve patient quality of life. However, in theory, ICS on neutrophil airway inflammation of COPD is not valid, point of view from clinical practice will not affect the ICS the natural course of COPD. Recent studies have shown, ICS reduce the acute exacerbation of COPD and COPD seems to be mainly associated with eosinophilic airway inflammation _6j. Therefore, ICS treatment of COPD, the benefits are limited. TORCH study did not show long-term treatment of COPD LABA has a negative result. While LABA treatment can not reduce COPD mortality, but it reduces the rate of acute exacerbations and improve lung function and quality of life similar to the role and ICS, was significantly better than placebo. These results are significant differences in SMART study, in which the reasons for that? Is the difference in the disease, ethnic differences, or the number of cases too small TORCH study? These issues remain to be more clinical trials to verify. In short, despite the TORCH study did not achieve the expected purpose, but there is still a milestone. It is the first time that COPD mortality endpoint drug intervention of large-scale multi-center trial. COPD is a
fora.pl
- załóż własne forum dyskusyjne za darmo
Theme
FrayCan
created by
spleen
&
Download
Powered by
phpBB
© 2001, 2005 phpBB Group
Regulamin